EP2983786A1 - Delivery of argon to a recipient of biological material - Google Patents

Delivery of argon to a recipient of biological material

Info

Publication number
EP2983786A1
EP2983786A1 EP14720667.6A EP14720667A EP2983786A1 EP 2983786 A1 EP2983786 A1 EP 2983786A1 EP 14720667 A EP14720667 A EP 14720667A EP 2983786 A1 EP2983786 A1 EP 2983786A1
Authority
EP
European Patent Office
Prior art keywords
biological material
recipient individual
composition according
recipient
argon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14720667.6A
Other languages
German (de)
French (fr)
Inventor
Ira Katz
Marc Lemaire
Jan Pype
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LAir Liquide SA pour lEtude et lExploitation des Procedes Georges Claude
Original Assignee
LAir Liquide SA pour lEtude et lExploitation des Procedes Georges Claude
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LAir Liquide SA pour lEtude et lExploitation des Procedes Georges Claude filed Critical LAir Liquide SA pour lEtude et lExploitation des Procedes Georges Claude
Publication of EP2983786A1 publication Critical patent/EP2983786A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to an argon-based gas or gas mixture intended to be administered to a recipient of biological material, such as an organ, in particular a human being, prior to, during and / or after the transplantation surgery operation. organ or tissues so as to protect said biological material before, during and / or after transplantation into the body of the recipient.
  • biological material such as an organ, in particular a human being
  • EP-A-2536272 teaches a liquid formulation comprising a liquid solution and at least one gas chosen from xenon, argon, hydrogen, H 2 S, helium, krypton, neon, radon or CO.
  • the gas is dissolved in the so-called liquid storage solution so as to conserve a biological material, in particular biological cells, tissues and organs, in particular an organ selected from the heart, the kidney, the liver, the pancreas and the body. 'intestine.
  • the gas is argon.
  • the problem is therefore to be able to avoid, reduce or minimize said ischemia-reperfusion injury by providing as effective protection as possible of biological material, including an organ or tissues.
  • the solution of the invention is a gaseous composition containing argon as an active gaseous compound selected for use in preventing or minimizing ischemia-reperfusion injury of biological material in a recipient individual, during and / or following the transplantation of said biological material into said recipient individual, said gaseous composition being administered to the recipient individual prior to, during and / or consecutive to the surgical operation for grafting the biological material into said recipient individual.
  • gaseous composition of the invention may comprise one or more of the following technical characteristics:
  • the biological material is an organ.
  • the biological material is a tissue, an organ or cells.
  • the biological material is an organ chosen from the liver, the kidneys, the lungs and the heart.
  • the active gaseous compound is mixed with an oxygen-containing gas, prior to its administration to the recipient individual.
  • the recipient individual is a human being, that is to say a man, a woman, a child, a newborn ...
  • it furthermore contains at least one additional active gaseous compound chosen from N 2 , Xe, H 2 , He, H 2 S, Kr, Ne, NO and CO.
  • a gaseous composition containing an argon gas mixed with oxygen can be used in a therapeutic treatment method aimed at preventing or minimizing an ischemia-reperfusion injury of a biological material in a recipient individual, such as a human being, during and / or subsequent to the transplantation of said biological material into said recipient individual, wherein said gaseous composition is administered to the recipient individual previously, during and / or consecutively to the surgical operation for grafting the biological material into said recipient individual.
  • the invention further relates to the use of argon for making a gaseous composition containing argon as an active gaseous compound for use in preventing or minimizing ischemia-reperfusion injury of biological material in a recipient individual during and / or subsequent to the transplantation of said biological material into said recipient individual, said gaseous composition being administered to the recipient individual prior to, during and / or consecutive to the surgical operation for grafting the biological material in said recipient individual.
  • the duration of administration of the gas is easily determinable on the basis of the duration of the anesthesia, by simple routine tests, depending on the organ to be implanted and the recipient individual considered.
  • a gaseous composition according to the invention formed of a gaseous mixture of argon and oxygen to prevent or minimize the ischemia-reperfusion injury of a biological material in a recipient individual
  • the animals used in the tests are pigs and mice, anesthetized and intubated / ventilated, and the biological material is the lung.
  • a virtual sampling of the animals 'lungs is performed by clamping said lung-related lungs, arteries and veins so as to obtain a total exclusion of the lungs from the animals' bodies tested in a manner identical to a real extraction.
  • the lungs of the animals are then ventilated for 4 hours, with the gaseous compositions tested.
  • the test composition (Ar / O 2 ) contains contents of Ar ranging from 15 to 80% by volume, the remainder being oxygen.
  • a group of control animals is treated in the same way but with gaseous mixtures of nitrogen and oxygen (N 2 / O 2 ) in the same proportions.
  • the gaseous compositions are administered to the animals by inhalation, the latter being intubated and supplied with gas by a respiratory fan.
  • the animals are sacrificed and the lungs are extracted and subjected to anatomical studies to determine the ischemic state, ie the presence of any lesions due to the period of ischemia-reperfusion.
  • compositions according to the invention based on argon, reduce the ischemia-reperfusion lesions, and their consequences on the good functioning of the lungs, unlike the animals of the control group having inhaled d-based mixtures. 'nitrogen.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention relates to a gaseous composition containing argon as an active gaseous compound for use to prevent or minimize an ischaemia-reperfusion lesion of a biological material in a recipient individual, during and/or subsequent to the transplantation of said biological material in said recipient individual, wherein said gaseous composition is administered to the recipient individual prior to, during and/or subsequent to the surgical operation aimed at grafting the biological material in said recipient individual.

Description

DELIVRANCE D'ARGON A UN RECEVEUR DE MATERIEL BIOLOGIQUE  DELIVRANCE D'ARGON HAS A RECEIVER OF BIOLOGICAL EQUIPMENT
La présente invention concerne un gaz ou mélange gazeux à base d'argon destiné à être administré à un receveur de matériel biologique, tel un organe, en particulier un être humain, préalablement à, pendant et/ou après l'opération chirurgicale de transplantation dudit organe ou desdits tissus de manière à protéger ledit matériel biologique avant, lors et/ou après sa transplantation dans le corps du receveur. The present invention relates to an argon-based gas or gas mixture intended to be administered to a recipient of biological material, such as an organ, in particular a human being, prior to, during and / or after the transplantation surgery operation. organ or tissues so as to protect said biological material before, during and / or after transplantation into the body of the recipient.
Le prélèvement de matériel biologique, c'est-à-dire d'un ou plusieurs organes et/ou tissus, chez un individu, appelé donneur, est un acte chirurgical à finalité thérapeutique conduisant à une greffe, c'est-à-dire à la réimplantation du matériel biologique, appelé greffon, chez un autre individu, appelé receveur.  The collection of biological material, that is to say one or more organs and / or tissues, in an individual, called a donor, is a surgical procedure for therapeutic purpose leading to a transplant, that is to say the reimplantation of the biological material, called graft, into another individual called the recipient.
Afin d'éviter ou minimiser les détériorations de ce matériel biologique, c'est-à-dire de ces organes et/ou tissus, il est nécessaire de les protéger avec des solutions spécifiques, dites de préservation, voire avec des gaz spécifiques, avec lesquels les organes et/ou tissus sont mis en contact après leur prélèvement.  In order to avoid or minimize the deterioration of this biological material, that is to say of these organs and / or tissues, it is necessary to protect them with specific solutions, called preservation solutions, or even with specific gases, with which organs and / or tissues are brought into contact after being removed.
Ainsi, le document EP-A-2536272 enseigne une formulation liquide comprenant une solution liquide et au moins un gaz choisi parmi le xénon, l'argon, l'hydrogène, le H2S, l'hélium, le krypton, le néon, le radon ou le CO. Le gaz est dissous dans la solution liquide dite de conservation de sorte de conserver une matière biologique, en particulier des cellules, des tissus et des organes biologiques, en particulier un organe choisi parmi le cœur, le rein, le foie, le pancréas et l'intestin. De préférence, le gaz est de l'argon. Thus, EP-A-2536272 teaches a liquid formulation comprising a liquid solution and at least one gas chosen from xenon, argon, hydrogen, H 2 S, helium, krypton, neon, radon or CO. The gas is dissolved in the so-called liquid storage solution so as to conserve a biological material, in particular biological cells, tissues and organs, in particular an organ selected from the heart, the kidney, the liver, the pancreas and the body. 'intestine. Preferably, the gas is argon.
Or, entre le moment du prélèvement et la mise en contact du matériel biologique avec le milieu de conservation, il peut se produire des détériorations dudit matériel biologique, notamment des lésions d'ischémie-reperfusion qui sont délétères pour le matériel biologique.  However, between the time of sampling and the contact of the biological material with the preservation medium, there may be damage to said biological material, including ischemia-reperfusion injury which is deleterious to the biological material.
Le problème est dès lors de pouvoir éviter, réduire ou minimiser lesdites lésions d'ischémie-reperfusion en opérant une protection aussi efficace que possible du matériel biologique, notamment d'un organe ou de tissus.  The problem is therefore to be able to avoid, reduce or minimize said ischemia-reperfusion injury by providing as effective protection as possible of biological material, including an organ or tissues.
La solution de l'invention est une composition gazeuse contenant de l'argon en tant que composé gazeux actif choisi pour une utilisation pour prévenir ou minimiser une lésion d'ischémie-reperfusion d'un matériel biologique chez un individu receveur, lors et/ou consécutivement à la transplantation dudit matériel biologique chez ledit individu receveur, ladite composition gazeuse étant administrée à l'individu receveur préalablement, pendant et/ou consécutivement à l'opération chirurgicale visant à greffer le matériel biologique chez ledit individu receveur. The solution of the invention is a gaseous composition containing argon as an active gaseous compound selected for use in preventing or minimizing ischemia-reperfusion injury of biological material in a recipient individual, during and / or following the transplantation of said biological material into said recipient individual, said gaseous composition being administered to the recipient individual prior to, during and / or consecutive to the surgical operation for grafting the biological material into said recipient individual.
Selon le cas, la composition gazeuse de l'invention peut comprendre l'une ou plusieurs des caractéristiques techniques suivantes :  Depending on the case, the gaseous composition of the invention may comprise one or more of the following technical characteristics:
- le matériel biologique est un organe.  - the biological material is an organ.
- elle contient entre 15 et 80% en volume dudit composé gazeux actif, c'est-à-dire d'argon.  it contains between 15 and 80% by volume of said active gaseous compound, that is to say of argon.
- le matériel biologique est un tissu, un organe ou des cellules.  - the biological material is a tissue, an organ or cells.
- le matériel biologique est un organe choisi parmi le foie, les reins, les poumons et le cœur.  - the biological material is an organ chosen from the liver, the kidneys, the lungs and the heart.
- le composé gazeux actif est mélangé avec un gaz contenant de l'oxygène, préalablement à son administration à l'individu receveur.  the active gaseous compound is mixed with an oxygen-containing gas, prior to its administration to the recipient individual.
- l'individu receveur est un être humain, c'est-à-dire un homme, une femme, un enfant, un nouveau né...  - the recipient individual is a human being, that is to say a man, a woman, a child, a newborn ...
- elle est administrée sous forme gazeuse par inhalation.  - It is administered in gaseous form by inhalation.
- elle contient en outre au moins un composé gazeux actif additionnel choisi parmi N2, Xe, H2, He, H2S, Kr, Ne, NO et CO. it furthermore contains at least one additional active gaseous compound chosen from N 2 , Xe, H 2 , He, H 2 S, Kr, Ne, NO and CO.
- elle contient éventuellement de l'oxygène.  it possibly contains oxygen.
- elle est constituée d'argon et d'oxygène pour le reste, c'est-à-dire un mélange gazeux Ar/02. - It consists of argon and oxygen for the rest, that is to say a gas mixture Ar / 0 2 .
- elle est sous forme gazeuse et est administrée par inhalation au moyen d'un masque respiratoire ou une sonde d'intubation.  it is in gaseous form and is administered by inhalation by means of a respiratory mask or an intubation probe.
- elle contient au moins 20% en volume dudit composé gazeux actif.  it contains at least 20% by volume of said active gaseous compound.
- elle contient au plus 60%> en volume dudit composé gazeux actif.  it contains at most 60% by volume of said active gaseous compound.
Plus généralement, dans le cadre de la présente invention, il a été mis en évidence que pour réduire les détériorations ou lésions résultant d'ischémies-reperfusions au sein d'organes ou autres tissus biologiques prélevés chez un individu donneur et destinés à être réimplantés et greffés chez un individu receveur, il convient d'agir préalablement à, pendant et/ou après l'opération chirurgicale visant à greffer lesdits organes ou tissus biologiques dans le corps du receveur en administrant une composition gazeuse protectrice à base d'argon au receveur.  More generally, in the context of the present invention, it has been demonstrated that to reduce deteriorations or lesions resulting from ischemia-reperfusions in organs or other biological tissues taken from a donor individual and intended to be reimplanted and grafted in a recipient individual, it is appropriate to act before, during and / or after the surgical operation for grafting said organs or biological tissues in the body of the recipient by administering an argon protective gaseous composition to the recipient.
En d'autres termes, une composition gazeuse contenant un gaz de type argon en mélange avec de l'oxygène, peut être utilisée dans une méthode de traitement thérapeutique visant à prévenir ou à minimiser une lésion d'ischémie-reperfusion d'un matériel biologique chez un individu receveur, tel un être humain, lors et/ou consécutivement à la transplantation dudit matériel biologique chez ledit individu receveur, dans laquelle ladite composition gazeuse est administrée à l'individu receveur préalablement, pendant et/ou consécutivement à l'opération chirurgicale visant à greffer le matériel biologique chez ledit individu receveur. In other words, a gaseous composition containing an argon gas mixed with oxygen can be used in a therapeutic treatment method aimed at preventing or minimizing an ischemia-reperfusion injury of a biological material in a recipient individual, such as a human being, during and / or subsequent to the transplantation of said biological material into said recipient individual, wherein said gaseous composition is administered to the recipient individual previously, during and / or consecutively to the surgical operation for grafting the biological material into said recipient individual.
L'invention concernant en outre une utilisation d'argon pour fabriquer une composition gazeuse contenant de l'argon en tant que composé gazeux actif pour une utilisation pour prévenir ou minimiser une lésion d'ischémie-reperfusion d'un matériel biologique chez un individu receveur, lors et/ou consécutivement à la transplantation dudit matériel biologique chez ledit individu receveur, ladite composition gazeuse étant administrée à l'individu receveur préalablement, pendant et/ou consécutivement à l'opération chirurgicale visant à greffer le matériel biologique chez ledit individu receveur.  The invention further relates to the use of argon for making a gaseous composition containing argon as an active gaseous compound for use in preventing or minimizing ischemia-reperfusion injury of biological material in a recipient individual during and / or subsequent to the transplantation of said biological material into said recipient individual, said gaseous composition being administered to the recipient individual prior to, during and / or consecutive to the surgical operation for grafting the biological material in said recipient individual.
La durée d'administration du gaz, est aisément déterminable sur la base de la durée de l'anesthésie, via de simples essais de routine, en fonction de l'organe à implanter et de l'individu receveur considéré.  The duration of administration of the gas is easily determinable on the basis of the duration of the anesthesia, by simple routine tests, depending on the organ to be implanted and the recipient individual considered.
Exemple illustratif Illustrative example
Afin de montrer l'efficacité d'une composition gazeuse selon l'invention formée d'un mélange gazeux d'argon et d'oxygène pour prévenir ou minimiser les lésions d'ischémie-reperfusion d'un matériel biologique chez un individu receveur, on utilise un modèle animal permettant de démontrer l'effet de l'administration de gaz, lors et/ou consécutivement à la transplantation dudit matériel biologique chez le receveur.  In order to show the effectiveness of a gaseous composition according to the invention formed of a gaseous mixture of argon and oxygen to prevent or minimize the ischemia-reperfusion injury of a biological material in a recipient individual, one uses an animal model to demonstrate the effect of gas administration, during and / or after transplantation of said biological material to the recipient.
Ici, les animaux ayant servi aux essais sont des porcs et des souris, anesthésiés et intubés/ventilés, et le matériel biologique est le poumon.  Here, the animals used in the tests are pigs and mice, anesthetized and intubated / ventilated, and the biological material is the lung.
Pour ce faire, on opère un prélèvement virtuel des poumons des animaux par clampage desdits poumons, des artères et des veines reliées aux poumons de manière à obtenir une exclusion totale des poumons du corps des animaux testés de manière identique à une extraction réelle.  To do this, a virtual sampling of the animals 'lungs is performed by clamping said lung-related lungs, arteries and veins so as to obtain a total exclusion of the lungs from the animals' bodies tested in a manner identical to a real extraction.
Une fois le clampage réalisé, on attend pendant une période d'environ 90 minutes, puis on opère un déclampage des poumons, veines et artères.  Once the clamping is done, one waits for a period of approximately 90 minutes, then one operates a declamping of the lungs, veins and arteries.
Les poumons des animaux sont alors ventilés pendant 4 heures, avec les compositions gazeuses testées.  The lungs of the animals are then ventilated for 4 hours, with the gaseous compositions tested.
La composition testée (Ar/02) contient des teneurs en Ar comprise entre 15 et 80% en volume, le reste étant de l'oxygène. Un groupe d'animaux témoins est traité de la même manière mais avec des mélanges gazeux d'azote et d'oxygène (N2/02) dans les mêmes proportions. The test composition (Ar / O 2 ) contains contents of Ar ranging from 15 to 80% by volume, the remainder being oxygen. A group of control animals is treated in the same way but with gaseous mixtures of nitrogen and oxygen (N 2 / O 2 ) in the same proportions.
Les compositions gazeuses sont administrées aux animaux par inhalation, ceux-ci étant intubés et alimentés en gaz par un ventilateur respiratoire.  The gaseous compositions are administered to the animals by inhalation, the latter being intubated and supplied with gas by a respiratory fan.
Ensuite, des tests de la fonction ventilatoire des poumons sont réalisés.  Then, tests of the ventilatory function of the lungs are carried out.
Puis, les animaux sont sacrifiés et les poumons sont extraits et soumis à des études anatomiques pour déterminer l'état ischémique, c'est-à-dire la présence de lésions éventuelles dues à la période d'ischémie-reperfusion.  Then, the animals are sacrificed and the lungs are extracted and subjected to anatomical studies to determine the ischemic state, ie the presence of any lesions due to the period of ischemia-reperfusion.
Les résultats obtenus montrent que les compositions selon l'invention, à base d'argon, diminuent les lésions d'ischémie-reperfusion, et leurs conséquences sur le bon fonctionnement des poumons, contrairement aux animaux du groupe témoin ayant inhalé des mélanges à base d'azote.  The results obtained show that the compositions according to the invention, based on argon, reduce the ischemia-reperfusion lesions, and their consequences on the good functioning of the lungs, unlike the animals of the control group having inhaled d-based mixtures. 'nitrogen.
Ces essais montrent l'intérêt à administrer une composition gazeuse selon l'invention à un individu receveur, préalablement, pendant et/ou consécutivement à l'opération chirurgicale visant à greffer un matériel biologique chez ledit individu receveur, en particulier un organe.  These tests show the interest in administering a gaseous composition according to the invention to a recipient individual, prior to, during and / or consecutive to the surgical operation for grafting biological material into said recipient individual, in particular an organ.

Claims

Revendications claims
1. Composition gazeuse contenant de l'argon en tant que composé gazeux actif pour une utilisation pour prévenir ou minimiser une lésion d'ischémie-reperfusion d'un matériel biologique chez un individu receveur, lors et/ou consécutivement à la transplantation dudit matériel biologique chez ledit individu receveur, ladite composition gazeuse étant administrée à l'individu receveur préalablement, pendant et/ou consécutivement à l'opération chirurgicale visant à greffer le matériel biologique chez ledit individu receveur. A gaseous composition containing argon as an active gaseous compound for use in preventing or minimizing ischemia-reperfusion injury of biological material in a recipient individual, upon and / or subsequent to the transplantation of said biological material in said recipient individual, said gaseous composition being administered to the recipient individual prior to, during and / or consecutive to the surgical operation for grafting the biological material in said recipient individual.
2. Composition selon la revendication précédente, caractérisée en ce qu'elle contient entre 15 et 80% en volume dudit composé gazeux actif. 2. Composition according to the preceding claim, characterized in that it contains between 15 and 80% by volume of said active gaseous compound.
3. Composition selon l'une des revendications précédentes, caractérisée en ce que le matériel biologique est un tissu, un organe ou des cellules. 3. Composition according to one of the preceding claims, characterized in that the biological material is a tissue, an organ or cells.
4. Composition selon l'une des revendications précédentes, caractérisée en ce que le matériel biologique est un organe. 4. Composition according to one of the preceding claims, characterized in that the biological material is an organ.
5. Composition selon l'une des revendications précédentes, caractérisée en ce que le matériel biologique est un organe choisi parmi le foie, les reins, les poumons et le cœur. 5. Composition according to one of the preceding claims, characterized in that the biological material is an organ selected from the liver, kidneys, lungs and heart.
6. Composition selon l'une des revendications précédentes, caractérisée en ce que le composé gazeux actif est mélangé avec un gaz contenant de l'oxygène, préalablement à son administration à l'individu receveur. 6. Composition according to one of the preceding claims, characterized in that the active gaseous compound is mixed with an oxygen-containing gas, prior to its administration to the recipient individual.
7. Composition selon l'une des revendications précédentes, caractérisée en ce que l'individu receveur est un être humain. 7. Composition according to one of the preceding claims, characterized in that the recipient individual is a human being.
8. Composition selon l'une des revendications précédentes, caractérisée en ce qu'elle contient au moins 20% en volume dudit composé gazeux actif et/ou au plus 60%> en volume dudit composé gazeux actif. 8. Composition according to one of the preceding claims, characterized in that it contains at least 20% by volume of said active gaseous compound and / or at most 60%> by volume of said active gaseous compound.
9. Composition selon l'une des revendications précédentes, caractérisée en ce qu'elle est administrée sous forme gazeuse par inhalation. 9. Composition according to one of the preceding claims, characterized in that it is administered in gaseous form by inhalation.
10. Composition selon l'une des revendications précédentes, caractérisée en ce qu'elle est constituée d'argon et d'oxygène. 10. Composition according to one of the preceding claims, characterized in that it consists of argon and oxygen.
EP14720667.6A 2013-04-12 2014-04-09 Delivery of argon to a recipient of biological material Withdrawn EP2983786A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1353313A FR3004350A1 (en) 2013-04-12 2013-04-12 DELIVERANCE OF MEDICAL GAS TO A RECEIVER OF BIOLOGICAL EQUIPMENT
PCT/FR2014/050847 WO2014167244A1 (en) 2013-04-12 2014-04-09 Delivery of argon to a recipient of biological material

Publications (1)

Publication Number Publication Date
EP2983786A1 true EP2983786A1 (en) 2016-02-17

Family

ID=48906290

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14720667.6A Withdrawn EP2983786A1 (en) 2013-04-12 2014-04-09 Delivery of argon to a recipient of biological material

Country Status (6)

Country Link
US (1) US20160051581A1 (en)
EP (1) EP2983786A1 (en)
CN (1) CN105102065A (en)
CA (1) CA2907966A1 (en)
FR (1) FR3004350A1 (en)
WO (1) WO2014167244A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6840834B2 (en) 2016-04-08 2021-03-10 モナトミクス テクノロジー Hypothermic inhalation gas composition
FR3049863B1 (en) * 2016-04-08 2018-05-11 Monatomics Technology INHALABLE HYPOTHERMIC GAS COMPOSITION
FR3049862A1 (en) * 2016-04-08 2017-10-13 Monatomics Tech THERMALLY NEUTRAL INHALABLE GAS COMPOSITION
US20210187121A1 (en) * 2017-04-28 2021-06-24 Benoit Prieur Cucurbituril derivatives as oxygen carriers
FR3114236B1 (en) * 2020-09-23 2023-08-04 Inst Nat Sante Rech Med Inhaled argon to treat a patient with cardiovascular disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007509091A (en) * 2003-10-21 2007-04-12 エイジーエイ、アクティエボラーグ Use of xenon for prevention of programmed cell death
EP1552840A1 (en) * 2004-01-07 2005-07-13 Aga Ab Use of a xenon/carbon monoxide mixture for the protection of cells
US20060239921A1 (en) * 2005-04-26 2006-10-26 Novadaq Technologies Inc. Real time vascular imaging during solid organ transplant
GB0520176D0 (en) * 2005-10-04 2005-11-09 Imp College Innovations Ltd Use
FR2956323B1 (en) * 2010-02-15 2013-12-20 Air Liquide ARGON-BASED INHALABLE GAS MEDICINE AGAINST PERIPHERAL ORGAN DEFECTS OR MALFUNCTIONS
FR2956289B1 (en) 2010-02-18 2014-09-19 Air Liquide LIQUID FORMULATION WITH DISSOLVED GASES FOR PRESERVING BIOLOGICAL MATERIAL

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2014167244A1 *

Also Published As

Publication number Publication date
FR3004350A1 (en) 2014-10-17
CA2907966A1 (en) 2014-10-16
WO2014167244A1 (en) 2014-10-16
CN105102065A (en) 2015-11-25
US20160051581A1 (en) 2016-02-25

Similar Documents

Publication Publication Date Title
EP2983786A1 (en) Delivery of argon to a recipient of biological material
MXPA03012031A (en) Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis.
JP2006514621A5 (en)
JP2005525848A (en) Treatment method of vascular disease
EP2536415B1 (en) Gaseous inhalable medicament comprising argon gas against peripheral organ deficiencies or failures
AU2004283448B2 (en) Use of xenon for the prevention of programmed cell death
Valsson et al. Effects of atrial natriuretic peptide on renal function after cardiac surgery and in cyclosporine-treated heart transplant recipients
JP6489535B2 (en) Protective agent for ischemia / reperfusion injury and method for treating organ
WO2005067945A2 (en) Use of a xenon/carbon monoxide mixture for the protection of cells
CA2507595A1 (en) Use of dextran sulfate in the treatment of instant blood-mediated inflammatory reaction
WO2014167245A1 (en) Supply of xenon or argon gas to a donor prior to taking a sample of biological material
WO2011154630A1 (en) Krypton-based inhalable gaseous medicinal product for combatting deficiencies or failure of peripheral organs
Altunkaya et al. Role of the nitric oxide pathway in ischemia-reperfusion injury in isolated perfused guinea pig lungs
DE10336768B4 (en) Drug for improving oxygenutilation
JP2017081862A (en) Pharmaceutical composition for reducing weight loss after extraction surgery
AU1745601A (en) Use of nitric oxide for the treatment of airway constriction
US7661424B2 (en) Method of use of gas mixtures to achieve nitrogen washout from the body and mitochondria of the heart
US20040142044A1 (en) Method of use of gas mixtures to achieve washout of nitrogen from the body and mitochondria
EP2986277B1 (en) Use of xenon for limiting tumour cell migration
Yamasaki et al. Twenty-four-hour preservation in γ-hydroxybutyrate improves lung function in a canine single-lung allotransplantation
DE10336778A1 (en) Inhalable medicament for stabilizing patients, e.g. during operations, useful e.g. for treating hypotension, shock, ischemia or reperfusion damage, comprising xenon
EP2461816A1 (en) Use of xenon for treating hypersensitivity to pain
FR2929513A1 (en) TREATMENT OF MIGRAINS WITHOUT AURA IN PREGNANT WOMEN BY INHALATION OF DIOXYGEN GASES.
PGD Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
Reich et al. Pathogenesis of pulmonary oxygen toxicity: role of systemic hyperoxia and convulsions

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20151112

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20160803

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20161003